Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Trial to Assess the Safety and Efficacy of Epcoritamab-containing Combination Salvage Therapy Followed by Autologous Stem Cell Transplantation and Epcoritamab Consolidation in Patients With Relapsed Large B-cell Lymphoma

NCT06287398 is registered in ClinicalTrials.gov with Australasian Leukaemia and Lymphoma Group as lead sponsor.

NCT NCT06287398
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06287398 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Trial to Assess the Safety and Efficacy of Epcoritamab-containing Combination Salvage Therapy Followed by Autologous Stem Cell Transplantation and Epcoritamab Consolidation in Patients With Relapsed Large B-cell Lymphoma
Lead sponsor
Australasian Leukaemia and Lymphoma Group
Phase
Phase 2
Overall status
Recruiting
Start date
December 11, 2023
Completion date
November 30, 2031
Enrollment
39 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dlbcl - diffuse large b cell lymphoma, dlbcl, nos genetic subtypes, follicular large cell lymphoma, follicular large cell lymphoma, relapsed, high grade b-cell lymphoma with myc and bcl2 or bcl6 rearrangements, high grade b-cell lymphoma, not otherwise specified, high-grade b-cell lymphoma